Asset profile
AV-1959R
Vaccine
Evidence outlook · lead readout
NCT06831812 · Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06831812: The trial was randomized and blinded with a placebo comparator, but it enrolled only 16 people in total, with as few as two per placebo group, and it was designed to test safety and antibody response rather than a disease outcome. No serious adverse events occurred in any group, but the very small numbers mean the safety comparison cannot rule much out.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.